- Home
- Publications
- Publication Search
- Publication Details
Title
Role of DNA repair defects in predicting immunotherapy response
Authors
Keywords
-
Journal
Biomarker Research
Volume 8, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-30
DOI
10.1186/s40364-020-00202-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer
- (2020) Daniel J. McGrail et al. CANCER CELL
- Tumor mutational burden (TMB) as a predictive biomarker of immune checkpoint blockade (ICB) in metastatic solid tumors.
- (2020) Chester Kao et al. JOURNAL OF CLINICAL ONCOLOGY
- Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review
- (2020) B. Pellegrino et al. Translational Oncology
- Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies
- (2020) Richard K. Yang et al. Oncotarget
- BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity
- (2019) Anne Margriet Heijink et al. Nature Communications
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
- (2019) Mary L. Disis et al. JAMA Oncology
- Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
- (2019) Triparna Sen et al. Cancer Discovery
- Base excision repair regulates PD-L1 expression in cancer cells
- (2019) Tiara Bunga Mayang Permata et al. ONCOGENE
- Association of DNA damage response and repair genes (DDR) mutations and microsatellite instability (MSI), PD-L1 expression, tumor mutational burden (TMB) in gastroesophageal cancers.
- (2019) Michael Cerniglia et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy
- (2019) Qiang Zhang et al. CANCER RESEARCH
- Mechanisms of Genomic Instability in Breast Cancer
- (2019) Pascal H.G. Duijf et al. TRENDS IN MOLECULAR MEDICINE
- Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
- (2019) Pengfei Zhao et al. Journal of Hematology & Oncology
- DNA sensing by the cGAS–STING pathway in health and disease
- (2019) Mona Motwani et al. NATURE REVIEWS GENETICS
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
- (2019) Panagiotis A. Konstantinopoulos et al. JAMA Oncology
- The BRCA2 mutation status shapes the immune phenotype of prostate cancer
- (2019) Maximilian Jenzer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression
- (2019) Alexander Thiem et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Prospects for combining immune checkpoint blockade with PARP inhibition
- (2019) Anping Li et al. Journal of Hematology & Oncology
- Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
- (2019) Akintunde Akinleye et al. Journal of Hematology & Oncology
- PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
- (2019) Yilun Wu et al. Frontiers in Immunology
- Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types
- (2019) Feng Wang et al. JAMA Oncology
- Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma
- (2019) David A. Braun et al. JAMA Oncology
- The Cytosolic DNA-Sensing cGAS–STING Pathway in Cancer
- (2019) John Kwon et al. Cancer Discovery
- The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma
- (2018) Anne M. Mills et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency
- (2018) Chaoyang Sun et al. CANCER CELL
- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
- (2018) Min Yuen Teo et al. JOURNAL OF CLINICAL ONCOLOGY
- The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer
- (2018) Tuo Li et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A Phase II Study of Pembrolizumab in EGFR-mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC
- (2018) A. Lisberg et al. Journal of Thoracic Oncology
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
- (2018) Diana Miao et al. SCIENCE
- Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers
- (2018) Daniel J. McGrail et al. Nature Communications
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Defective Replication Stress Response Is Inherently Linked to the Cancer Stem Cell Phenotype
- (2018) Daniel J. McGrail et al. Cell Reports
- Cancer Drugs Approved Based on Biomarkers and Not Tumor Type—FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers
- (2018) Vinay Prasad et al. JAMA Oncology
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Development of PARP and Immune-Checkpoint Inhibitor Combinations
- (2018) Ross A Stewart et al. CANCER RESEARCH
- PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
- (2018) Jianfeng Shen et al. CANCER RESEARCH
- Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
- (2017) Suzanne George et al. IMMUNITY
- Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
- (2017) Jung-Min Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- (2017) Fred R. Hirsch et al. Journal of Thoracic Oncology
- DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel
- (2017) Kazuya Takamochi et al. LUNG CANCER
- First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
- (2017) Steven Lemery et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- DNA Damage and Repair Biomarkers of Immunotherapy Response
- (2017) Kent W. Mouw et al. Cancer Discovery
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers
- (2017) Andrew R. Green et al. Cancer Immunology Research
- Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma
- (2017) Ashton A. Connor et al. JAMA Oncology
- Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and aBRCAmutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy
- (2016) Ursula A. Matulonis et al. CANCER
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Mutational Landscape and Sensitivity to Immune Checkpoint Blockers
- (2016) R. M. Chabanon et al. CLINICAL CANCER RESEARCH
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
- (2016) Janice M. Mehnert et al. JOURNAL OF CLINICAL INVESTIGATION
- Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
- (2016) Eileen E. Parkes et al. JNCI-Journal of the National Cancer Institute
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- (2016) F Stephen Hodi et al. LANCET ONCOLOGY
- Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing
- (2016) Qi Chen et al. NATURE IMMUNOLOGY
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
- (2016) Kyle C. Strickland et al. Oncotarget
- Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
- (2016) Eileen E. Parkes et al. JNCI-Journal of the National Cancer Institute
- Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
- (2016) Joseph McLaughlin et al. JAMA Oncology
- POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
- (2015) I. C. van Gool et al. CLINICAL CANCER RESEARCH
- DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers
- (2015) Masafumi Kato et al. Journal of Gynecologic Oncology
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
- (2015) Brooke E. Howitt et al. JAMA Oncology
- Risk of Prostate Cancer in Lynch Syndrome: A Systematic Review and Meta-analysis
- (2014) S. Ryan et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
- (2014) Nicolas J. Llosa et al. Cancer Discovery
- The causes and consequences of genetic heterogeneity in cancer evolution
- (2013) Rebecca A. Burrell et al. NATURE
- The DNA damage response and cancer therapy
- (2012) Christopher J. Lord et al. NATURE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of PARP in DNA repair and its therapeutic exploitation
- (2011) M Javle et al. BRITISH JOURNAL OF CANCER
- Making Sense of Missense in Lynch Syndrome: The Clinical Perspective
- (2010) H. T. Lynch et al. Cancer Prevention Research
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colorectal carcinomas in MUTYH-associated polyposis display histopathological similarities to microsatellite unstable carcinomas
- (2009) Maartje Nielsen et al. BMC CANCER
- Deficient DNA Mismatch Repair Is Common in Lynch Syndrome-Associated Colorectal Adenomas
- (2009) Maria Simona Pino et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity
- (2009) James E. Cleaver et al. NATURE REVIEWS GENETICS
- Immune Response Against Frameshift-Induced Neopeptides in HNPCC Patients and Healthy HNPCC Mutation Carriers
- (2008) Yvette Schwitalle et al. GASTROENTEROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More